A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion

Christian Torp-Pedersen; Dimitar H Raev; Garth Dickinson; Noam N Butterfield; Brian Mangal; Gregory N Beatch

doi:http://dx.doi.org/10.1161/CIRCEP.111.962340

A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion

Christian Torp-Pedersen, Dimitar H Raev, Garth Dickinson, Noam N Butterfield, Brian Mangal, Gregory N Beatch

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

37 Citationer (Scopus)

Abstract

Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.

Originalsprog	Engelsk
Tidsskrift	Circulation. Arrhythmia and Electrophysiology
Vol/bind	4
Udgave nummer	5
Sider (fra-til)	637-43
Antal sider	7
ISSN	1941-3149
DOI	https://doi.org/10.1161/CIRCEP.111.962340
Status	Udgivet - 2011

Adgang til dokumentet

http://dx.doi.org/10.1161/CIRCEP.111.962340

Citationsformater

A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. / Torp-Pedersen, Christian; Raev, Dimitar H; Dickinson, Garth; Butterfield, Noam N; Mangal, Brian; Beatch, Gregory N.

I: Circulation. Arrhythmia and Electrophysiology, Bind 4, Nr. 5, 2011, s. 637-43.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{4f3e94acac2e4569ab4e69f15de9ae8d,

title = "A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion",

abstract = "Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.",

author = "Christian Torp-Pedersen and Raev, {Dimitar H} and Garth Dickinson and Butterfield, {Noam N} and Brian Mangal and Beatch, {Gregory N}",

year = "2011",

doi = "http://dx.doi.org/10.1161/CIRCEP.111.962340",

language = "English",

volume = "4",

pages = "637--43",

journal = "Circulation: Arrhythmia and Electrophysiology",

issn = "1941-3149",

publisher = "Lippincott Williams & Wilkins",

number = "5",

}

TY - JOUR

T1 - A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion

AU - Torp-Pedersen, Christian

AU - Raev, Dimitar H

AU - Dickinson, Garth

AU - Butterfield, Noam N

AU - Mangal, Brian

AU - Beatch, Gregory N

PY - 2011

Y1 - 2011

N2 - Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.

AB - Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.

U2 - http://dx.doi.org/10.1161/CIRCEP.111.962340

DO - http://dx.doi.org/10.1161/CIRCEP.111.962340

M3 - Journal article

VL - 4

SP - 637

EP - 643

JO - Circulation: Arrhythmia and Electrophysiology

JF - Circulation: Arrhythmia and Electrophysiology

SN - 1941-3149

IS - 5

ER -